Navigation Links
MEDIHONEY Used to Prevent Amputation of Patient's Leg

Clinicians at major NY hospital tout MEDIHONEY(TM) at press conference

PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that MEDIHONEY was the focus of a major press conference last week at North Shore Long Island Jewish Hospital in Manhasset, NY. At the press conference, clinicians detailed the case of a patient who appeared to be heading towards a lower extremity amputation (LEA) due to a non-healing wound associated with an extremely rare fungal infection.

Video clips of the press conference were subsequently aired on several new broadcasts throughout the NY region. To view these clips, please go to the following links:,0,7667575.story

According to Mary Brennan, RN, CWOCN, Clinical Nurse Specialist for Wounds at North Shore, "MEDIHONEY helped to turn this wound around for him and allowed us back on track for healing. We had used other therapies, but this was the product that made the difference in a very short time."

There are over 50,000 LEAs each year in the United States alone. The 3-year mortality rate post-LEA is estimated to be around 50%.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from the University of Southern California in Q4 of 2007. For more information about Derma Sciences, Inc., visit its home page on the Internet at

    Contact: Derma Sciences, Inc.             Allen & Caron Inc
             Edward J. Quilty                 Rudy Barrio (US Investors)
             Chairman and CEO       
             (609) 514-4744                   Brian Kennedy (media)
                                              (212) 691-8087

SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Derma Sciences Launches Two New MEDIHONEY(TM) Formulations
2. Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter
3. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference
4. Derma Sciences MEDIHONEY(TM) Profiled By ABC News Philadelphia Affiliate
5. Derma Sciences Receives Third FDA Clearance for MEDIHONEY(TM) Wound & Burn Dressings
6. New Study Shows the Use of MEDIHONEY(TM) Wound & Burn Dressing is Associated With Reduction in Wound Size
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
9. American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness
10. College of American Pathologists Offers Tips on Simple Diabetes Prevention in the New Year
11. Photos: Arthritis Foundation Launches Nationwide Movement Encouraging People to Move to Prevent and Treat Arthritis
Post Your Comments:
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in ... time the doctor uses other traditional cutting tools, such as the scalpel and high-speed ...
(Date:11/24/2015)... ... 2015 , ... In an article published November 12th by Obesity ... are or are not eligible for bariatric surgery. The article explains that candidates for ... than 100 pounds overweight, or have a BMI of 35 and over with at ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Developmental, commercial, and regulatory/legal ... profitability of pharmaceutical products, says GBI Research ... regulatory/legal strategies all play a key role in boosting ... . --> Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ...
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... HILL, N.C. , Nov. 24, 2015  In ... research projects in an effort to quickly uncover new ... position. --> --> ... launch a market research project and ensure that all ... company and industry standards. Another major barrier to efficiently ...
Breaking Medicine Technology: